Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer

CONCLUSION: Addition of ganitumab to CP chemotherapy in primary EOC did not improve PFS. Our results do not support further study of ganitumab in unselected EOC patients.PMID:34642026 | DOI:10.1016/j.ygyno.2021.09.025

Source: Gynecologic Oncology - October 13, 2021 Category: Cancer & Oncology Authors: G E Konecny A E Wahner Hendrickson T M Davidson B J Winterhoff S Ma S Mahner J Sehouli P A Fasching G Feisel-Schwickardi M Poelcher L D Roman A Rody B Y Karlan S A Mullany H Chen I L Ray-Coquard D M Provencher A Yachnin P H Cottu J A Glaspy P Haluska D J Source Type: research